Author

James A. Bolognese

Observed names: Bolognese, James A., J A Bolognese, J Bolognese, J. A. Bolognese, J. Bolognese, J.A Bolognese, J.A. Bolognese, James A Bolognese, James Bolognese

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), National Board of Health and Welfare, University of Graz, Regeneron (United States), Norfolk and Norwich University Hospital, The Royal Free Hospital, Nottingham City Hospital, Cytel (United States)

OpenAlex ID: A5032780756

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

2005 · Robert S. Bresalier, Robert S. Sandler, et al. · New England Journal of Medicine · 2,525

PDF

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

2006 · Christopher P Cannon, Sean P Curtis, et al. · The Lancet · 524

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis

1999 · Loren Laine, Sean Harper, et al. · Gastroenterology · 474

PDF

A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas

2006 · John A. Baron, Robert S. Sandler, et al. · Gastroenterology · 433

Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.

2000 · E W Ehrich, G M Davies, et al. · PubMed · 430

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial

2000 · Christopher Hawkey, Loren Laine, et al. · Arthritis & Rheumatism · 371

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain

2015 · Eugene R. Viscusi, Lynn Webster, et al. · Pain · 206

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

1982 · J A Tobert, G D Bell, et al. · Journal of Clinical Investigation · 202

PDF

Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1999 · F. L. Lanza, M. F. Rack, et al. · Alimentary Pharmacology & Therapeutics · 166

Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis

2000 · Douglas J. Watson, Sean E. Harper, et al. · Archives of Internal Medicine · 164

Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement

2003 · J.A Bolognese, T.J Schnitzer, et al. · Osteoarthritis and Cartilage · 140

PDF

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis

2023 · Arun J. Sanyal, Sudha S. Shankar, et al. · Nature Medicine · 131

PDF

An Intra-Articular, Extended-Release Formulation of Triamcinolone Acetonide Prolongs and Amplifies Analgesic Effect in Patients with Osteoarthritis of the Knee

2015 · Neil Bodick, Joelle Lufkin, et al. · Journal of Bone and Joint Surgery · 129

Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

2023 · James A. Simon, Richard A. Anderson, et al. · Menopause The Journal of The North American Menopause Society · 93

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

2005 · Dena R. Ramey, Douglas J. Watson, et al. · Current Medical Research and Opinion · 91

Pharmacokinetics of repeated single oral doses of enalapril maleate (mk‐421) in normal volunteers

1984 · Alice E. Till, Hector J. Gomez, et al. · Biopharmaceutics & Drug Disposition · 87

Prolonged Oral Treatment with MK-677, a Novel Growth Hormone Secretagogue, Improves Sleep Quality in Man

2008 · Georges Copinschi, Rachel Leproult, et al. · Neuroendocrinology · 85

A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis

2001 · K. E. Truitt, R. S. Sperling, et al. · Aging Clinical and Experimental Research · 78

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects

2000 · Richard H Hunt, Barry Bowen, et al. · The American Journal of Medicine · 76

Correlation Between Arterial FDG Uptake and Biomarkers in Peripheral Artery Disease

2012 · Kelly S. Myers, James H.F. Rudd, et al. · JACC. Cardiovascular imaging · 69

PDF

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis

2006 · Christopher P. Cannon, Sean P. Curtis, et al. · American Heart Journal · 69

Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain

2010 · David J. Hewitt, Tony W. Ho, et al. · Pain · 60

Validation of a symptoms questionnaire for benign prostatic hyperplasia

1992 · James A. Bolognese, Placido B. Grino, et al. · The Prostate · 59

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

2001 · C. J. Hawkey, L. Laine, et al. · Alimentary Pharmacology & Therapeutics · 57

PDF

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis

2018 · Isabelle Sermet-Gaudelus, John P. Clancy, et al. · Journal of Cystic Fibrosis · 56

PDF

Works count: 92

Citation count: 7,561

H-index: 32

I10-index: 54